The AmiC/NlpD pathway dominates peptidoglycan breakdown in *Neisseria meningitidis* and affects cell separation, NOD1 agonist production, and infection

Jia Mun Chan, Kathleen T. Hackett, Katelynn L. Woodhams, Ryan E. Schaub, and Joseph P. Dillard*

University of Wisconsin-Madison
Department of Medical Microbiology and Immunology
School of Medicine and Public Health
Madison, WI 53705

*To whom correspondence should be addressed:
Email: joe.dillard@wisc.edu
Mailing address: 1550 Linden Dr., 4157 Microbial Sciences Building, Madison WI 53706
Phone: (608) 265-2837
Fax: (608) 262-8418

ABSTRACT

The human-restricted pathogen *Neisseria meningitidis*, which is best known for causing invasive meningococcal disease, has a nonpathogenic lifestyle as an asymptomatic colonizer of the human naso- and oropharyngeal space. *N. meningitidis* releases small peptidoglycan (PG) fragments during growth. It was demonstrated previously that *N. meningitidis* releases low levels of tripeptide PG monomer, which is an inflammatory molecule recognized by the human intracellular innate immune receptor NOD1. In this present study, we demonstrated that *N. meningitidis* released more PG-derived peptides compared to PG monomers. Using a reporter cell line overexpressing human NOD1, we showed that *N. meningitidis* activates NOD1 using PG-derived peptides. Generation of such peptides required the presence of the periplasmic *N*-acetylmuramyl-L-alanine amidase AmiC, and the outer membrane lipoprotein, NlpD. AmiC and NlpD were found to function in cell separation, and mutation of either *amiC* or *nlpD* resulted in large clumps of unseparated *N. meningitidis* cells instead of the characteristic diplococci. Using stochastic optical reconstruction microscopy, we demonstrated that FLAG epitope-tagged NlpD localized to the septum, while similarly-tagged AmiC was found at the septum in some diplococci but distributed around the cell in most cases. In a human whole blood infection assay, an *nlpD* mutant was severely attenuated and showed particular sensitivity to complement. Thus, in *N. meningitidis* the cell separation proteins AmiC and NlpD are necessary for NOD1 stimulation and for survival during infection of human blood.

INTRODUCTION

Neisseria meningitidis, also known as the meningococcus, is an obligate colonizer of the human nasopharyngeal space. Meningococci occasionally disseminate to cause invasive disease such as meningitis and septicemia. Invasive disease has a fatality rate around 11% even with early treatment, and 11-19% of survivors develop lifelong sequelae [1-3]. *N. meningitidis* colonizes up to 25% of the population at any one time [3]. The carriage rate of *N. meningitidis* can be as high as 70% in areas of high density such as military barracks, college dormitories, and during the Hajj pilgrimage [3, 4]; prolonged exposure to carriers increases the risk of invasive meningococcal disease for non-carriers [4]. *N. meningitidis* encodes multiple virulence factors that allow it to invade the bloodstream and cross the blood-brain barrier, cause a large inflammatory response, and evade clearance by the immune system [5, 6]. Much of the tissue damage sustained during meningococcal disease is a result of a strong inflammatory immune response [3, 6, 7]. One class of immunostimulatory molecules made and released by *N. meningitidis* is diaminopimelic acid (DAP)-type peptidoglycan fragments [8].

Peptidoglycan (PG) is a structural macromolecule that confers bacterial cell shape and protects the cell against turgor pressure. It is made of repeating subunits of *N*-acetylglucosamine (GlcNAc) and *N*-acetylmuramic acid (MurNAc), with peptide chains attached to the *N*-acetylmuramic acid moiety [9]. The third amino acid on this peptide chain is DAP in most Gram-negative bacteria and Gram-positive bacilli, and lysine in most other Gram-positive bacteria [10]. Breakdown of existing PG strands and incorporation of newly synthesized PG strands allow for cell enlargement and cell separation [11], and this process generates small PG fragments as the bacteria grow [12, 13]. Most Gram-negative bacteria release very small amounts of PG fragments; instead, PG fragments are typically contained in the periplasmic space and efficiently

taken back into the cytoplasm by a PG fragment permease in order to be reused in cellular processes [13, 14]. A limited group of Gram-negative bacteria, including but not limited to *N. meningitidis,* the closely related pathogen *N. gonorrhoeae*, the etiological agent of whooping cough *Bordetella pertussis*, and the squid symbiont *Vibrio fischeri* release cytotoxic PG monomers (GlcNAc-anhydroMurNAc-peptide) with no overt effects on bacterial growth [8, 12, 15, 16]. PG monomers released from *N. gonorrhoeae* cause ciliated cell death in human Fallopian tubes [15, 17]. In addition to releasing PG monomers, *N. meningitidis* also releases PG dimers (two glycosidically- or peptide-linked monomers), and PG-derived sugars such as GlcNAc-anhydroMurNAc disaccharide and anhydroMurNAc [8]. The release of PG-derived peptides by *N. meningitidis* has not been characterized.

Host organisms such as humans have evolved strategies to detect and respond to microbe associated molecular patterns to either prevent or resolve an infection. One such intracellular innate immune receptor is human NOD1 (hNOD1). hNOD1 induces a proinflammatory response upon recognition of PG fragments with a terminal DAP, which includes tripeptide PG monomers (GlcNAc-anhydroMurNAc-L-ala-D-glu-*meso*DAP) and PG derived tripeptide (L-ala-D-glu-*meso*DAP) [18-21]. hNOD1 does not respond well to amidated PG fragments; some species of Gram-positive bacteria that have DAP-type PG, such as *Bacillus subtilis*, amidate the DAP moiety of their PG stems [19, 20, 22]. Thus, hNOD1 predominantly detects the presence of Gram-negative bacteria, which includes *N. meningitidis*. In this study, we characterized PG-derived peptides released by *N. meningitidis* and found that meningococci release immunologically relevant amounts of hNOD1 activating PG-derived peptides.

RESULTS

The Ltg and the AmiC pathways of sacculus degradation. Previous studies of PG fragment breakdown and release by *N. meningitidis*, *N. gonorrhoeae*, and commensal species indicate that PG can be broken down in two different ways (Fig. 1) [15]. In the lytic transglycosylase-dominated pathway, LtgA removes peptide-crosslinked dimers from the sacculus, and an endolytic lytic transglycosylase, likely LtgE, creates glycosidically-linked dimers [23, 24]. After DacB (PBP3) cuts crosslinks between strands, LtgA and LtgD degrade strands to PG monomers [8, 25]. LdcA acts on the tetrapeptide PG monomers to convert them to tripeptide PG monomers, thus making them NOD1 agonists [26, 27]. For the AmiC-dependent pathway, strand separation by DacB is followed by a stripping of the peptides from the strands by AmiC, with NlpD activation [28, 29]. AmiC cannot remove the final peptide [28, 30]. LtgC then degrades the nearly-naked glycan strand, creating free disaccharides and tetrasaccharide-peptide [31, 32]. NagZ breaks down the disaccharides into monosaccharides [33], and NlpC is predicted to break down tetrapeptides [34]. Although both pathways are active in all *Neisseria* species studied, the lytic transglycosylase pathway is slightly favored in *N. gonorrhoeae*. PG monomers are the most abundant PG fragments released by gonococci, but free tri- and tetrapeptides are almost as abundant as PG monomers [28, 35]. In *N. meningitidis*, experiments monitoring ^{3}H-glucosamine-labeled PG suggest that the AmiC pathway is favored. Free sugars and tetrasaccharide-peptide make up a larger proportion of PG fragments released by *N. meningitidis* than do PG monomers and dimers [8]. If *N. meningitidis* extensively uses the AmiC pathway, then this species may make significant amounts of NOD1 agonist in the form of free tripeptides.

We examined PG fragment release in *N. meningitidis* using pulse-chase, metabolic labeling with [2,6-^{3}H] DAP. PG fragments released into the medium during growth were

analyzed by size-exclusion chromatography (Fig. 2A). Five major peaks were observed, and these contain PG dimers, tetrasaccharide-peptide, PG monomers, free tri- and tetrapeptides, and free dipeptides [8, 35]. The amounts of PG in the free tri- and tetrapeptide and dipeptide fractions were much greater than those in the PG dimer and monomer fractions. These data indicate that *N. meningitidis* extensively degrades its PG to free peptides and sugars prior to release and that it favors the AmiC-dependent pathway for PG breakdown.

Released tri- and tetrapeptides from PG have been characterized in *N. gonorrhoeae*. Sinha and Rosenthal demonstrated that the peptides were composed of Ala-Glu-DAP and Ala-Glu-DAP-Ala and that they were not crosslinked [35]. Lenz et al. found that an *N. gonorrhoeae* mutant defective for *amiC* did not release free tri- and tetrapeptides [28]. The second PG-derived peptide peak (dipeptides) has been noted previously but not thoroughly investigated, partly because it overlaps somewhat with the peak for free single amino acids not incorporated in the labeling process (Fig 2A), [12, 36]. *Escherichia coli* is known to release the disaccharide DAP-Ala [37]. Therefore, we tested whether metabolic labeling with [3H]D-Ala would label the released dipeptide. Incorporation of [3H]D-Ala in this peak was similar to incorporation of [3H]DAP, indicating that for *N. meningitidis*, as with *E. coli*, the released dipeptide fraction may contain DAP-D-Ala.

Mutation of *amiC* or *nlpD* abolishes peptide release. *N. meningitidis* encodes one periplasmic *N*-acetylmuramyl-L-alanine amidase, AmiC [38]. Meningococcal AmiC is predicted to be a 417-amino acid zinc-dependent metalloprotease with a Tat signal sequence, an N-terminal AMIN domain that binds PG, and a C-terminal catalytic domain that cleaves peptide stems. AmiC homologues in *E. coli* and *N. gonorrhoeae* function as cell separation amidases [30, 39]. To

examine the role of meningococcal AmiC in PG fragment production and release, we generated

an in-frame markerless deletion of *amiC*. Mutation of *amiC* abolished PG peptide release and

resulted in an increase in PG multimer release (Fig. 2B). If AmiC were able to cleave PG

monomers, we would expect to see a proportional increase in PG monomer release with the

decrease in peptide release by the *amiC* mutant. However, there is no significant difference in

PG monomer release between WT and the *amiC* mutant. Complementation of *amiC* from an

ectopic locus restored almost WT distributions of released PG fragments. Our results suggest that

meningococcal AmiC liberates peptide stems from the sacculi, and it is necessary for the release

of both free tri- and tetrapeptides and free dipeptide.

NlpD is a putative AmiC activator protein and functions to potentiate the amidase activity

of AmiC in *N. gonorrhoeae* and *E. coli* [28, 29]. Meningococcal NlpD is predicted to be a 415-

amino acid outer membrane lipoprotein with two LysM PG binding domains and a degenerate

LytM/M23 peptidase domain. Like NlpD homologues from *N. gonorrhoeae* and *E. coli*, only 2/4

of the active site residues in the M23 peptidase domain of meningococcal NlpD are conserved

[29, 40]. Analyses in *N. gonorrhoeae* and *E. coli* indicate that their NlpD homologues do not

have enzymatic function, but instead act as activator proteins for the amidases [28, 29, 40].

Mutation of *nlpD* in *N. meningitidis* abolished free peptide release without affecting release of

PG monomers and dimers (Figure 2C). Complementation of *nlpD* at an ectopic site partially

rescued peptide release. We conclude that AmiC and NlpD are indispensable for PG-derived

peptide release in *N. meningitidis* and that AmiC activity is dependent on activation by NlpD.

PG-derived peptides released by *N. meningitidis* stimulate NOD1 activation. HEK293

reporter cell lines overexpressing NOD receptors were used to determine if peptide release by

meningococci is necessary for induction of a NOD-dependent response. In this assay, NOD activation is measured by determining the amount of NF-κB controlled secreted alkaline phosphatase (SEAP) detected in the medium via a colorimetric assay. HEK293 cells overexpressing human NOD1 were treated with cell-free supernatant from WT, *amiC* mutant, *nlpD* mutant, or induced cultures of the respective *amiC* or *nlpD* complementation strains (Fig. 3A). As described previously and demonstrated here, supernatant from *N. meningitidis* engenders a NOD1-dependent response (Fig. 3, [8]). We found that supernatant from WT *N. meningitidis* induced 3.6x and 7.5x higher levels of human NOD1 activation compared to an *amiC* or an *nlpD* mutant, respectively (Fig. 3A). Supernatant from *amiC* and *nlpD* complementation strains showed a partial phenotypic complementation, with 2x and 3x higher NOD1 responses compared to supernatant from the mutant strains, respectively ($p < 0.05$) (Fig. 3A).

We also treated an HEK293 cell line overexpressing human NOD2 in parallel with the same supernatant samples as used for the NOD1 experiments (Fig. 3B). The intracellular innate immune receptor NOD2 recognizes muramyl-dipeptide (MDP) and responds to reducing end PG monomers and thus would not be expected to be differentially affected by amounts of free peptides [41-43]. As predicted, treatment with supernatant from *amiC* or *nlpD* mutants did not alter NOD2 activation levels. Thus, we conclude that PG-derived peptides generated by the action of AmiC and NlpD in *N. meningitidis* induce a NOD1 response, but do not activate NOD2 in a human epithelial cell line.

AmiC and NlpD are required for cell separation. Periplasmic *N*-acetylmuramyl-L-alanine amidases that act on the sacculi cleave septal PG to allow for proper cell separation [30, 44]. To examine the role of meningococcal AmiC and NlpD in cell separation, we performed thin-

section transmission electron microscopy (TEM) to visualize the cell morphology of WT, mutant, and complementation strains. We counted the numbers of cells presenting as monococci, diplococci, tetrads, and 5+ cell clusters in 16-24 fields/strain. Each field used in quantification had an average of 30 cells; an example of a field for each strain used for quantification is shown in Figure 4A. A higher-magnification image demonstrating the size of the multi-cell clumps of the *amiC* and *nlpD* mutants is also included.

WT cells predominantly presented as diplococci (60%) and monococci (26%), with few cells found as tetrads (13%) and 5+ cell clusters (1%) (Fig. 4A and 4C). In contrast, both *amiC* and *nlpD* mutants formed large aggregates of 5 cells or more (94% and 76%, respectively). Mutation of *amiC* caused a more severe cell separation defect than did mutation of *nlpD*, as more cells were found in large clusters and fewer cells were found as diplococci or monococci (Fig. 4A and 4C). Only 3% each of *amiC* mutant cells presented as diplococci and monococci, while 10% and 4% of *nlpD* mutants presented as diplococci and monococci, respectively (Fig 4C). Both *amiC* and *nlpD* complementation strains showed WT-like cell morphology, with most cells presenting as diplococci (57% and 55%, respectively) and monococci (37% and 35%), respectively (Fig 4C). We conclude that AmiC and NlpD are required for proper cell separation in *N. meningitidis*.

C-terminal FLAG3 tagged AmiC displayed both septal and distributed localization while tagged NlpD is septally-localized. We generated C-terminal triple FLAG epitope tagged versions of AmiC and NlpD to visualize localization of these proteins in the cell via stochastic optical reconstruction microscopy (STORM). To determine functionality of these tagged proteins, we performed TEM to look at the cell morphology of the *amiC:FLAG3*[+] and

nlpD:FLAG3[+] expressing strains (Fig. 4B). The *nlpD:FLAG3*[+] strain predominantly presented as diplococci (46%) and monococci (24%), although it had more 5+ cell clusters compared to WT (17% vs 1%). In contrast, *amiC:FLAG3*[+] cells were more likely to be found in clumps of 5 or more cells (50%) with only 22% and 18% of cells presenting as diplococci and monococci (Fig. 4C). However, the cell clumps in an *amiC:FLAG3*[+] mutant were much smaller and contained fewer cells than the large cell clusters formed by an *amiC* or an *nlpD* mutant, suggesting that AmiC:FLAG3 is partially functional for cell separation.

Localizations of AmiC:FLAG3 and NlpD:FLAG3 in *N. meningitidis* were determined using STORM, and chromosomal DNA was counterstained with DAPI and visualized by epifluorescence microscopy to determine the position of the cells. The presence of a signal band between two adjacent DAPI foci (cells) was interpreted as septal localization. We observed two types of localization patterns for AmiC:FLAG3 (Fig. 5). First, AmiC:FLAG3 localized to the putative septum in a small subset of cells (Fig. 5, left panels). Second, we observed peripheral distribution of AmiC:FLAG3 for most cells in both diplococcal and larger aggregates. NlpD:FLAG3 was clearly localized to the septum in nearly all cells, with a few cells showing some staining that might extend beyond the septum (Fig. 5, right panels). Since the FLAG3 tag had some effects on function of the two proteins (Fig. 4C), more so for AmiC and less for NlpD, we cannot rule out an effect of the tag on protein localization. However, our observations are similar to the known recruitment of the *E. coli* AmiC and NlpD homologues to the septum during late cell division [39, 45]. Peripheral distribution of AmiC and NlpD homologues in *E. coli* are also seen in non-dividing cells, with a minor enrichment of *E. coli* AmiC at the poles of such cells [39]. Our findings suggest that AmiC:FLAG3 localizes to the septum in dividing meningococcal cells, and may be distributed around the cell in non-dividing cells.

Infection of human whole blood. The severe cell separation defects of the *amiC* and *nlpD* mutants might be expected to affect infection, and differences in the release of PG fragments might affect phagocyte function. However, a significant difficulty in testing the infection ability of such mutants is the inability to accurately quantify the number of viable bacterial cells following infection, since each CFU for the mutants contains multiple bacterial cells stuck together. To circumvent this difficulty, we used the *nlpD* mutant carrying an inducible complement construct. In the absence of the anhydro-tetracycline inducer, the mutant grows as unseparated cell clusters. However, after 4h of growth in medium containing anhydro-tetracycline, a wild-type level of cell separation is achieved (Fig. 6A). Thus we could get a reflection of CFU numbers from infection by growing the bacteria from each timepoint with inducer and then dilution plating the then-separated bacteria.

We compared the ability of the WT strain and the *nlpD* mutant to survive in whole human blood. When we attempted this experiment in an encapsulated strain background, no difference was seen between the WT and mutant. However, in unencapsulated strains, the *nlpD* mutant exhibited a substantial defect. Upon addition of the bacteria to the blood, CFU numbers for the WT strain dropped, reaching ~50% by 2h and then growing to 170% by 4h (Fig. 6B). By contrast, the *nlpD* mutant dropped 45-fold upon addition to blood and continued to decrease in numbers. By 4h, the *nlpD* mutant had dropped more than 2000-fold. When we used cobra venom factor (CVF) to deplete complement in the blood before bacterial addition, the initial decrease in CFU numbers for the WT strain was eliminated, and the initial decrease for the *nlpD* mutant was reduced to only a two-fold effect. After that point, the WT strain in the CVF-treated blood maintained CFU numbers for the first two hours, then grew to over nine-fold the starting value

(Fig. 6B). The *nlpD* mutant in the CVF-treated blood died at the same rate as the *nlpD* mutant

did in untreated blood, albeit with CFU values 20-40 fold higher at each time point. A control

experiment in which the WT or *nlpD* mutant were incubated in diluted tissue culture medium

demonstrated that the *nlpD* mutant is not defective in survival in nutrient poor medium (Fig. S1).

When we incubated the WT or *nlpD* mutant with human serum, the survival of the mutant was

not significantly different from that of the WT and trended toward better survival for the mutant

(Fig. S2). Overall, these results demonstrate that the *nlpD* mutant has a defect in survival in

human blood and that a large part of that defect is mediated by complement but not complement

alone. Even when complement is depleted, the *nlpD* mutant also shows a survival defect,

suggesting increased killing by other soluble factors or phagocytes.

DISCUSSION

These studies demonstrated that the major PG fragments released by *N. meningitidis* are

PG-derived peptides, with the most abundant species being the free tripeptide and tetrapeptide.

The tri- and tetrapeptides are also released in large amounts by the related species *N.*

gonorrhoeae, though *N. meningitidis* releases much greater amounts of the peptides than *N.*

gonorrhoeae. The peptides are generated by the action of the periplasmic *N*-acetylmuramyl-L-

alanine amidase AmiC, which is activated by the outer membrane lipoprotein NlpD. Mutation of

either *amiC* or *nlpD* in *N. meningitidis* completely abolished PG-derived peptide release (Fig. 2).

AmiC and NlpD were also necessary for generating the free dipeptide. The enzyme responsible

for dipeptide production has not been characterized in *Neisseria* spp., but three NlpC family

endopeptidases are encoded in the meningococcal genome and these enzymes generally function

to cleave the gamma-D-Glu-DAP bond [46]. The requirement for AmiC and NlpD for making

the dipeptide suggests that the tetrapeptide must first be cleaved from the glycan strand by AmiC before the endopeptidase can act on it. In support of this idea, some NlpC family enzymes have been found to require a free N-terminal L-alanine for peptides to serve as substrates for these enzymes [34].

Mutation of *amiC* or *nlpD* led to a significant reduction in NOD1 activation. This result is consistent with the loss of free tripeptide release in these mutants. It is well established that human NOD1 responds to PG fragments containing gamma-D-Glu-DAP and that terminate with DAP, which would include the free tripeptide released by meningococci [18-20, 22]. In studies of *N. gonorrhoeae*, neither abolishing free peptide release nor abolishing disaccharide-tripeptide monomer release reduced NOD1 activation, indicating that production of either the tripeptides or the disaccharide-tripeptide monomers was sufficient for stimulating NOD1 [28]. Our results with *N. meningitidis* indicate that the free tripeptides are the major NOD1 agonists for this species and emphasize that meningococci rely on the AmiC-mediated pathway for most PG degradation (Fig. 1 and 2). Meningococci release lower levels of tripeptide PG monomer compared to gonococci, and meningococcal supernatant induces lower NOD1 activation in HEK293 cells and IL-8 production by Fallopian tube explants compared to gonococcal supernatant [8]. Increased release of PG monomers by gonococci is partly due to a somewhat defective version of AmpG, the PG fragment permease, leading to decreased recycling efficiency for anhydro-disaccharide containing PG fragments. However, *ampG* is not fully responsible for the differences in fragment release between gonococci and meningococci since replacement of the meningococcal *ampG* with that of gonococci only somewhat increased PG monomer release, and this meningococcal strain continued to show the more extensive degradation of PG fragments to free disaccharides and anhydro-muramic acid [36]. Taken together with these published observations, our results

provide support to the hypothesis that *N. meningitidis* degrades PG fragments more extensively compared to *N. gonorrhoeae* and thereby reduces NOD1 activation, which may reduce immune clearance during asymptomatic colonization.

It is not currently clear how PG fragment release contributes to meningococcal lifestyle. In response to a NOD1 agonist or other inflammatory molecules, oral epithelial cells alter gene expression without inducing an inflammatory response [47]. Still, it is not particularly surprising that PG fragments released by meningococci do not induce inflammation in nasopharyngeal tissue, since asymptomatic colonization is by definition non-overtly damaging to the host on the organismal level. Released PG fragments may play a role in the establishment of colonization, in the invasion of the meninges or in exacerbating damage during invasive meningococcal disease, or in colonization of new niches such as the urethra (11, 55).

Consistent with the role of AmiC as a cell separation amidase, mutation of *amiC* or *nlpD* led to cell separation defects, which manifested as large cell clusters containing more than 10 cells (Fig. 4). STORM analyses revealed that in a small subset of cells, AmiC:FLAG3 formed a banding pattern at the septum, suggesting septal localization of this protein. In a larger subset of cells, AmiC:FLAG3 was found randomly distributed around the cell. NlpD:FLAG3 signal was found to localize to the septum. Such localization patterns suggest that NlpD is a septal protein and that AmiC is recruited to the septum during cell division, as observed in other species of bacteria [39, 45, 48].

The growth of the *amiC* mutant and the *nlpD* mutant as large aggregates of cells led us to test whether the cell separation deficiency might alter infection proficiency. In other systems, bacterial variants that grow as filaments have been found to have a survival advantage over normal bacilli and to avoid phagocytic killing [49]. However, gonococci defective for *amiC*,

while not showing a growth defect, were sensitive to killing by deoxycholate, suggesting

membrane instability [30]. Also, a meningococcal mutant lacking *gna33* (*ltgC*) showed a cell

separation defect and was unable to infect infant rats in a model of septicemia [32]. We used a

human whole blood infection model and infected the blood with the WT strain or an *nlpD* mutant

carrying an inducible *nlpD* expression construct. While the WT strain was able to survive and

grow in blood, the *nlpD* mutant showed more than a thousand fold defect in survival over 4h.

The survival defect was still present, though substantially lessened, when blood depleted for

complement was used for infections. Neither incubation in dilute medium nor incubation with

human serum recapitulated the decreased survival phenotype. These results indicate that in

addition to complement, other factors present in blood, such as phagocytes, are necessary for the

increased death of the non-separating mutant.

Overall, these studies demonstrated that *N. meningitidis* AmiC and NlpD are necessary

for the producing the free peptides released by the bacteria and that meningococci favor this

pathway for cell wall degradation. AmiC and NlpD are necessary for cell separation, and a cell

separation mutant is defective in survival in an ex vivo model of human blood infection.

MATERIALS AND METHODS

Bacterial strains and growth conditions. All strains used in this study are listed in Table 1.

Except where indicated, all meningococcal strains used in the experiments are unencapsulated

derivatives of *N. meningitidis* (ATCC 13102 *cap⁻*)*,* in which the capsule biosynthesis gene *siaD*

has been interrupted with a chloramphenicol marker [8]. These strains also have a point mutation

in *rpsL* conferring streptomycin resistance [8]. *N. meningitidis* strains were grown on gonococcal

base medium (GCB) agar (Difco) plates at 37°C with 5% CO_2 or in gonococcal base liquid

medium (Difco) with 0.042% bicarbonate [50] and Kellogg's supplements [51] (cGCBL) at 37°C with aeration. *Escherichia coli* strains were grown on LB agar (Difco) plates at 37°C or in LB liquid medium at 37°C. When needed, 10 µg/ml chloramphenicol, 10 µg/ml erythromycin, or 80 µg/ml kanamycin was added to *N. meningitidis* cultures. For *E. coli*, 100 µg/ml ampicillin, 25 µg/ml chloramphenicol, 500 µg/ml erythromycin, or 40 µg/ml kanamycin was added to the media when appropriate. When necessary, 0.1 mM or 1 mM IPTG, or 2 ng/ml anhydrotetracycline was added to the media to induce expression of a target gene.

Strain construction. *N. meningitidis* mutants were generated by spot transformation [52]. Briefly, 20 µg linearized plasmid DNA or PCR product was spotted onto a GCB agar plate and allowed to dry. Subsequently, 5-10 piliated colonies were streaked over the DNA spots, and the plate was incubated overnight at 37°C with 5% CO_2. Successful transformants were either selected using antibiotics, or identified by PCR screening. All transformants were confirmed by PCR and DNA sequencing. Due to the difficulty of transforming *amiC* and *nlpD* mutants, complementation strains were constructed by first transforming the WT with the complementation construct, followed by transformation of the resulting strains with the deletion construct. EC1026 is the only strain generated by transformation with a PCR product. This PCR product was generated by PCR amplification of *nlpD* from WT *N. meningitidis* chromosomal DNA using primer NlpD DUS F and NlpD DUS R (Table 2), which resulted in a DNA fragment containing the *nlpD* coding sequence flanked by DNA uptake sequences (DUS) to facilitate uptake and recombination [53]. Transformation with this PCR product corrected the *nlpD* sequence at the complementation locus to the WT sequence.

Plasmid construction. All plasmids used in this study are listed in Table 1 and were verified by PCR and sequencing. All primers are listed in Table 2. Plasmids were generated by ligation of a vector backbone and an insert, and transformed into Rapid Trans™ chemically competent TAM1 cells (Active Motif).

Two plasmids, pKL24 and pKL25, were generated to create an in-frame deletion of *amiC*. To make pKL24 (*amiC* deletion in pKH6), pDG005 and pKH6 were digested with XmaI and SacI. The *amiC* deletion insert from pDG005 was ligated into pKH6 generating pKL24. To generate pKL25 (*ermC rpsL* in pKL24; final construct Δ*amiC::ermCrpsL*), the *ermC rpsL* positive/negative selection cassette was first excised from pKC1 by digestion with NheI and EcoRV. The insert from pKC1 was blunted with T4 polymerase and ligated into the blunted BspHI site from pKL24 to create pKL25.

Three plasmids were generated to create a *nlpD* insertional inactivation mutant. To create pKL28 (*nlpD* and flanking DNA in pKH6), PCR was used to amplify *nlpD* and flanking DNA with primers SacII nlpD F and SacI nlpD R. The PCR product and pKH6 were digested with SacI and SacII, then ligated. To generate pKL29 (*nlpD* deletion in pKH6), primers BglII nlpD del F and BglII nlpD del R were used in a PCR with pKL28 as a template. The product was digested with BglII and self-ligated to make pKL29, which contains a markerless *nlpD* deletion with flanking DNA. To build pKL38 (Δ*nlpD::kan* allelic replacement in pKH6), the kanamycin resistance marker from pKH99 was excised by digestion with EcoRV and Ecl136II and inserted into the blunted BglII site of pKL29.

Two plasmids, pKL45 and pKL49, were constructed to complement an *nlpD* mutation at an ectopic site. Plasmid pKL45 (*nlpD** in pMR68) was made by first amplifying *nlpD* from WT *N. meningitidis* chromosomal DNA with primers SacI nlpD F2 and SpeI nlpD R. The PCR

product and pMR68 were subsequently digested with SacI and SpeI and ligated to each other. Despite repeated attempts, the resulting plasmid contained one or more mutations in the *nlpD* coding sequence. We deduce that the presence of a second copy of *nlpD* in *E. coli* is toxic to the bacterium, and saved one of the plasmids as pKL45. pKL45 has a nonsense mutation leading to a premature stop codon at the third codon. Plasmid pKL49 (*nlpD*-rpsL* in pMR68) was generated by insertion of *rpsL* into pKL48. *rpsL* was amplified from pKC1 using primers MluI rspL F and MluI rpsL R; the PCR product and pKL45 were digested with MluI and subsequently ligated to each other to generate pKL49.

Plasmid pKL50 was generated to complement an *amiC* mutation at an ectopic site. To make pKL50 (*amiC* in pMR33), *amiC* was amplified from WT *N. meningitidis* chromosomal DNA with primers SacI MC amiC F and SpeI MC amiC R and digested with SacI and SpeI. pMR33 was digested similarly, and ligated with the digested *amiC* PCR product.

Plasmid pEC140 was built to create a deletion/insertion mutant where *kan* replaced *amiC*. To generate pEC140 (*amiC::kan* in pIDN3), pDG005 was first digested with BspHI and subsequently blunted with T4 DNA polymerase. The *aph3* gene conferring resistance against kanamycin (referred to as *kan^R*) was amplified from pHSS6 using primers kan F BamHI and kan R BamHI and blunt-ligated with the blunted, BspHI digested pDG005 to form pEC140.

To epitope tag *amiC* at the native locus, pEC169 (*amiC':FLAG3^+ -3'* flank in pIDN3) was constructed in multiple steps. First, *amiC* 3' flank region was amplified using primers HindIII MC amiC down F and XhoI MC amiC down R and WT *N. meningitidis* chromosomal DNA as a template. pMR100 and the PCR product were digested with HindIII and XhoI, and ligated to make pEC167 (*amiC* 3' flank in pMR100). The partial coding sequence of *amiC* lacking the start codon, signal sequence and stop codon (*amiC'*) was amplified from WT *N.*

meningitidis DNA using primers SacI MC amiC –sigseq F and EcoRI MC amiC –stop codon R, digested with SacI and EcoRI and ligated into similarly digested pEC167 to form pEC169.

To epitope tag *nlpD* at the native locus, pEC173 (*nlpD':FLAG3⁺-kanᴿ*-3' flank in pIDN3) was generated with a similar strategy as pEC169. *nlpD* 3' flank region was amplified using primers HindIII MC nlpD down F and XhoI MC nlpD down R instead, digested with HindIII and XhoI and ligated with similarly digested pMR100 to form pEC168. The partial coding sequence of *nlpD* lacking the start codon, signal sequence and stop codon (*nlpD'*) was amplified with primers SacI MC nlpD –sigseq F and EcoRI MC nlpD –stop codon R, digested with SacI and EcoRI and ligated into similarly digested pEC168 to form pEC170. pEC170 was digested with HindIII, blunted with T4 polymerase and ligated with *kanᴿ* to form pEC173.

Metabolic labeling of peptidoglycan and quantitative fragment release. Metabolic labeling of PG and quantitative fragment release was performed as described previously [54]. Strains were pulse-chased labeled with 25 μg/ml [2,6-^{3}H] DAP in DMEM lacking cysteine supplemented with 100 μg/ml methionine and 100 μg/ml threonine for 45 minutes. A sample of the culture was removed to determine the number of radioactive counts per minute (CPM) by liquid scintillation counting, and the bacteria were diluted to obtain equal CPM in each culture. After a 2 hour chase period, supernatant was harvested by centrifuging the culture at 3,000 x *g* for 10 mins, and filter-sterilizing the supernatant with a 0.22 μm filter. [2,6-^{3}H] DAP labeled molecules in the filtered supernatant were then separated using tandem size-exclusion chromatography with 0.1 M LiCl as the mobile phase, and detected by liquid scintillation counting. The growth medium for the *amiC* and *nlpD* complementation strains was supplemented with 0.1 mM IPTG and 2 ng/ml anhydrotetracyline, respectively.

Thin section transmission electron microscopy. *N. meningitidis* strains were grown in cGCBL until mid-log phase, when cells were harvested by centrifugation at 17, 000 x *g* for 1 minute. Growth medium for the *amiC* and *nlpD* complementation strains contained 0.1 mM IPTG or 2 ng/ml anhydrotetracycline, respectively, for gene induction. Cells were washed once with PBS and resuspended in fixative solution (2% paraformaldehye, 2.5% glutaraldehye in 0.1M phosphate buffer). Thin section electron microscopy of fixed samples was done at the University of Wisconsin-Madison Medical School Electron Microscope Facility. Enumeration of meningococci in cell clusters were done by counting the number of complete, in plane cells presenting as monococci, diplococci, tetrads or clusters of five or more cells in 16-24 fields/strain containing an average of 30 cells/field.

Treatment of HEK293 reporter cell line with filtered supernatant from meningococcal cultures. HEK293-Blue cells that encode secreted alkaline phosphatase (SEAP) under the control of an NF-κB promoter (parental cell lines NULL1 and NULL2) and hNOD1 or hNOD2 receptors (NOD and NOD2 cell lines) were grown, maintained and treated according to the manufacturer's instructions (InvivoGen). Supernatant samples were harvested from meningococcal cultures started at OD_{540} of 0.2 and grown for 2 hours by centrifugation at 17,000 x *g* for 1 minute and filter sterilized using a 0.22 μm pore filter. Cultures were supplemented with 1 mM IPTG or 2 ng/ml anhydrotetracycline as needed. Supernatant samples were normalized to total cellular protein. HEK293 cells that were seeded at a density of 2.8 x 10^5 cells/ml (NOD1/NULL1) or 1.4 x 10^5 cells/ml (NOD2/NULL2) in 180 μl DMEM with 4.5g/L glucose, 2 mM L-glutamine and 10% heat inactivated fetal bovine serum (FBS) were treated with 20 μl supernatant for 18 hours at 37°C with 5% CO_2. A total volume of 20 μl each of

cGCBL (media only control), 10 µg/ml TriDAP (positive control for NOD1/NULL1) (InvivoGen) or 10 µg/ml muramyl dipeptide (MDP; positive control for NOD2/NULL2) (InvivoGen), 10 µg/ml Tri-Lys (negative control for NOD1/NULL1) or 10 µg/ml MDP-control (MDP-c; negative control for NOD2/NULL2) (InvivoGen) were used as treatment controls. After 18 hours of treatment, 20 µl HEK293 culture supernatant was added to 180 µl QUANTI-Blue reagent (InvivoGen) and incubated at 37°C for 4 hours. SEAP activity was determined by measuring absorbance at 650 nm. To calculate NF-κB dependent hNOD activation (graphed SEAP levels (A_{650})), A_{650} values from NULL1 or NULL2 controls were subtracted from the corresponding A_{650} values from NOD1 or NOD2 treatments. Results are from four independent experiments, and statistical tests were performed using Student's *t*-test.

Stochastic optical reconstruction microscopy (STORM). Sample preparation and imaging was done as described previously [23]. Meningococcal cultures were grown to mid-log phase and harvested by centrifugation at 17,000 x *g* for 2 minutes. Cells were washed once with PBS, and suspended in 400 µl fixative solution (4% methanol-free formaldehyde in PBS). The cell suspensions were first incubated at RT for 15 minutes, and then on ice for 15 minutes. The cell suspensions were then centrifuged at 6,000 x *g* and the fixative solution discarded. Cells were quickly washed thrice with cold PBS to ensure thorough removal of fixative solution, and resuspended in cold GTE buffer (50 mM glucose, 1mM EDTA, 20 mM Tris-HCl pH 7.5) and incubated on ice for 10 minutes. Cells were quickly washed with PBS-T (0.3% Triton-X100 in PBS), suspended in cold methanol and incubated at -20°C for a minimum of 10 minutes. Methanol was removed, after which cells were washed with PBS-T for 5 minutes, blocked with 400 µl 5% goat serum in PBS-T for 15 minutes, and incubated with 1:150 diluted M2 primary

antibody (Sigma) in PBS for 1 hour. Cells were subsequently washed with PBS thrice, and incubated with 200 µl 1:100 diluted AlexaFluor-647 (Thermo Fisher) secondary antibody, 100 ng/ml DAPI and 5% goat serum in PBS for 1 hour at RT or O/N at 4°C. Cells were washed with PBS five times and suspended in 200 µl PBS to remove unbound antibody and dye. Around 2 µl volumes of the samples were spotted onto poly-L-lysine coated coverslips, mounted with VECTASHIELD^TM H-1000 mounting media (Vector laboratories) and visualized using a Nikon N-STORM microscope. Images were analyzed using the software NIS-Elements AR with N-STORM analysis. Linear brightness/contrast adjustments and false-coloring was performed using FIJI.

Human blood infection assay. Blood was collected from healthy donors using hirudin-containing vacutainer tubes [55]. All human subjects gave written informed consent in accordance with a protocol approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board (Protocol #2017-1179). *N. meningitidis* was grown overnight on a GCB agar plate and harvested into phosphate-buffered saline. The blood was inoculated with *N. meningitidis* strains at 1 x 10^8 CFU/ml bacteria, and the cultures were grown with rotation at 37°C. To enumerate *N. meningitidis* used as the inoculum at the start of the experiment, the bacteria were inoculated into GCBL instead of blood and dilution plated. By contrast, t=0 was the time point taken immediately after inoculation of the blood. Where indicated, blood was pretreated with 1µg/ml cobra venom factor for 1 hour prior to inoculation, with the blood culture rotating at 37°C. At each time point 375µl of each blood culture was removed and diluted into 1.125ml of cGCBL medium. Anhydrotetracycline (final concentration 2ng/ml) was added to each culture. The diluted cultures were grown at 37°C for 4 hours to allow for expression from

the complementation construct. After 4 hours, the bacteria were diluted and plated for CFU

determinations. Incubations in dilute medium were performed in the same manner as for blood

except that the bacteria were suspended in DMEM diluted 1:8 in phosphate-buffered saline.

Serum resistance assay. *N. meningitidis* were suspended in cGCBL and grown for 2h with

aeration to reach log phase. Log phase bacteria were diluted to an OD_{540} of 0.2 and resuspended

in DMEM. Four 1:10 dilutions of the culture were performed, and the fourth dilution was treated

with 25% human serum at 37°C. At 0 and 30 mins, 25 µl of each culture was plated for CFU

counts. To prepare the heat-killed control serum, the serum was incubation at 56°C for 30 min.

Figure 1. Peptidoglycan degradation pathways in *Neisseria* species. During growth, portions of the sacculus are degraded to allow for cell wall enlargement or remodeling. In the lytic transglycosylase-dominated pathway (top), PG dimers are liberated by LtgA and LtgE, strands are degraded to monomers by LtgA and LtgD, and a majority of PG monomers have their peptides shortened to three amino acids by LdcA. In the amidase-dominated pathway (bottom), peptides are removed from PG strands by AmiC, which is activated by NlpD. Free peptides may be further degraded to dipeptides by one of the three NlpC enzymes. LtgC degrades the denuded strand to free disaccharides and tetrasaccharide-peptide. NagZ, a cytosolic enzyme, cleaves the disaccharides into monosaccharides. Molecules shown with boxes around them are released from the bacteria into the milieu.

Figure 2. Peptidoglycan fragment release from growing *N. meningitidis*. A) [2,6-^{3}H] DAP-labeled PG fragments released by WT *N. meningitidis* (ATCC 13102 *cap$^-$*) were separated by size-exclusion chromatography, resolving into five distinct peaks in the included volume. Cartoons above each peak show the structures of the PG fragments, representing, in order from the left, dimers, tetrasaccharide-peptide, monomers, free tetra- and tri-peptide, and free dipeptides. Symbols used are based on Jacobs *et al.* (35). The structures of the dipeptides are not yet chemically confirmed. B) PG fragment release from an *amiC* mutant (KL1065) and complement (EC1020). C) PG fragment release from an *nlpD* mutant (KL1072) and complement (EC1026). Mutation of *amiC* (B) or *nlpD* (C) abolished the release of PG-derived peptides. Genetic complementation of the *amiC* (B) and *nlpD* (C) mutations partially restored release of PG-derived peptides. Results depicted are representative of three experiments.

Figure 3. Stimulation of human NOD1 or human NOD2 by conditioned media from *N. meningitidis* mutants that do not release PG-derived peptides. Supernatants from WT (ATCC 13102 *cap*⁻), *amiC* mutant (KL1065), *amiC* complementation (EC1020), *nlpD* mutant (KL1072), and *nlpD* complementation (EC1026) strains were harvested, normalized to total cellular protein and used to treat HEK293 reporter cell lines overexpressing hNOD1 (A) or hNOD2 (B), as well as parental HEK293 cell lines. hNOD activation was determined by measuring the amount of secreted alkaline phosphatase (SEAP) in the media. The values presented are the SEAP levels measured as A_{650} for the hNOD overexpressing strain minus those of the parental strain lacking hNOD overexpression, i.e., A_{650} (hNOD1) – A_{650} (NULL1) or A_{650} (hNOD2) – A_{650} (NULL2). Error bars represent the standard deviation. Results are from three independent experiments, with technical triplicates for each biological replicate. Statistical significance was determined by Student's *t*-test, in which * indicates $p < 0.05$.

Figure 4. Cell separation defects in *amiC* or *nlpD* mutants. A) WT, *amiC* mutant and complementation strains (KL1065, EC1020), *nlpD* mutant and complementation strains (KL1072, EC1026), as well as B) strains expressing *amiC:FLAG3*⁺ (EC1032) and *nlpD:FLAG3*⁺ (EC1033) were imaged by thin-section transmission electron microscopy. C) Quantification of the number of cells presenting as monococci, diplococci, tetrads, and clumps of 5+ cells in 16-24 fields of view containing an average of 30 cells each were performed, and presented as percent of total cells.

Figure 5. Localization of AmiC:FLAG3 and NlpD:FLAG3 in the meningococcal cell. Localizations of AmiC:FLAG3 or NlpD:FLAG3 were determined using STORM. DNA was

counterstained with DAPI. Localization of AmiC:FLAG3 is presented in the left panels, and

localization of NlpD:FLAG3 is presented in the right panels. Septal localization of the proteins is

seen when they form an approximate line between the two DAPI-stained cells of a diplococcus.

As NlpD:FLAG3 exhibited near full functionality, a single field with multiple diplococci was

easily found and shown, whereas AmiC:FLAG3 was only partially functional, making it

necessary to gather images of diplococci or small clumps from several fields.

Figure 6. Survival in human whole blood. An *nlpD* mutant with a tightly-regulated

complementation construct (EC1026) was used to examine the effect of a cell separation defect

on infection. A) Schematic showing the method used for enumerating bacteria following blood

infection. Approximately equal numbers of WT and mutant bacteria were used to infect human

blood in vitro, though they give different CFU counts due to the *nlpD* mutant not separating. At

each time point, the bacteria were diluted into GCBL medium containing anhydrotetracycline to

induce *nlpD* expression in the complemented strain, and after 4h of growth the bacteria were

diluted and plated to determine CFU numbers. Thin-section transmission electron microscopy

shows that EC1026 exhibits the cell separation defect without induction, but 4h in the presence

of anhydrotetracycline results in separation to individual diplococci and monococci. B) WT

(ATCC13102 *cap*⁻) and *nlpD* mutant (EC1026) were inoculated into hirudin-treated human

blood. Where indicated, CVF was used to deplete complement in the blood before inoculation.

Because of the difficulties inherent in getting equal numbers of separating and not separating

bacteria for the initial inoculation, the data were plotted as the ratio of final CFUs to initial CFUs

at each time point, on a log scale. Statistical significance was determined by Student's *t*-test, in

which * indicates p<0.05 compared to WT, and # indicates p<0.05 compared to WT + CVF.

These data are the geometric mean $\pm$ standard error of the mean from five independent experiments.

Table 1. Strains used in this study.

Strain	Description	Reference or source
N. meningitidis		
ATCC 13102 Str	ATCC 13102 *rpsL*K43R	[56]
ATCC 13102 *cap-*	ATCC 13102 *rpsL*K43R *siaD::cat* (WT *N. meningitidis*)	[8]
KL1060	ATCC 13102 Str transformed with pKL25; ATCC 13102 Str Δ*amiC::ermCrpsL*	This study
KL1061	KL1060 transformed with pDG005; ATCC 13102 Str Δ*amiC*	This study
KL1065	KL1061 transformed with pHC10; ATCC 13102 *cap-* Δ*amiC*	This study
KL1071	ATCC 13102 Str transformed with pKL38; ATCC 13102 Str Δ*nlpD::kan*	This study
KL1072	KL1071 transformed with pHC10; ATCC 13102 *cap-* Δ*nlpD::kan*	This study
EC1018	ATCC 13102 *cap-* transformed with pKL50; ATCC 13102 *cap-* P_{IPTG}-*amiC*	This study
EC1020	EC1018 transformed with pEC140; ATCC 13102 *cap- amiC::kan* P_{IPTG}-*amiC*	This study
EC1022	ATCC 13102 *cap-* transformed with pKL49; ATCC 13102 *cap-* P_{tet}-*nlpD**-*rpsL*	This study
EC1024	EC1022 transformed with pKL38; ATCC 13102 *cap- nlpD::kan* P_{tet}-*nlpD**-*rpsL*	This study
EC1026	EC1024 transformed with PCR amplified *nlpD*; ATCC 13102 *cap-* Δ*nlpD::kan* P_{tet}-*nlpD*	This study
EC1032	13102 *cap-* transformed with pEC169; ATCC 13102 *cap- amiC:FLAG3+*	This study
EC1033	13102 *cap-* transformed with pEC173; ATCC 13102 *cap- nlpD:FLAG3+-kan*	This study
Plasmids		
pDG005	Markerless *amiC* deletion in pIDN3	[30]
pHC10	Serogroup C *siaD::cat*	[57]
pHSS6	Cloning vector; source of *aph3* gene (referred to as *kan^R*)	[58]
pKC1	Positive/negative selection plasmid for *Neisseria* spp.; source of *rpsL*	[59]
pKH6	Cloning vector derived from pIDN1 and pGCC6	[56]
pKH99	Cloning vector derived from pHSS6 and pIDN2; source of *kan^R*	[56]
pMR33	Complementation vector; IPTG inducible	[60]
pMR68	Complementation vector; anhydrotetracycline inducible	[60]
pMR100	Cloning vector pIDN3 with a C-terminal FLAG3 sequence	[61]
pKL24	*amiC* deletion insert from pDG005 into pKH6	This study
pKL25	*ermCrpsL* in pKL24; Δ*amiC::ermCrpsL* in pKH6	This study
pKL28	*nlpD* and flanking DNA in pKH6	This study
pKL29	Markerless *nlpD* deletion in pIDN3; Δ*nlpD* in pIDN3	This study
pKL38	*kan^R* in pKL29; Δ*nlpD::kan* in pIDN3	This study
pKL45	*nlpD** in pMR68 (has premature stop codon)	This study
pKL49	*nlpD**-*rpsL* in pMR68	This study
pKL50	*amiC* in pMR33	This study
pEC140	*kan^R* from pHSS6 in pDG005; Δ*amiC::kan* in pIDN3	This study
pEC167	*amiC* 3' flank in pMR100	This study
pEC168	*nlpD* 3' flank in pMR100	This study
pEC169	Partial *amiC* coding sequence (*amiC'*) in pEC167; *amiC':FLAG3+* -3' flank in pIDN3	This study

| pEC170 | Partial *nlpD* coding sequence (*nlpD'*) in pEC168 | This study |
| pEC173 | *kan^R* in pEC170; *nlpD':FLAG3^+-kan^R*-3' flank in pIDN3 | This study |

Table 2. Primers used in this study. Restriction enzyme sites are underlined.

Primer	Sequence
SacII nlpD F	TAACCGCGGAGGCACTGTGGACATTGTTG
SacI nlpD R	GATTGAGCTCTCACGATGGTTGCGGTCAAAG
BglII nlpD del F	GCCGAGATCTAGCTATATCGCGTTCTGACTTTC
BglII nlpD del R	GCCCAGATCTCATAAGATAACCTTCATGTTCCG
SacI nlpD F2	GCCGGAGCTCATCGGAACATGAAGGTTATC
SpeI nlpD R	GCCGACTAGTGATTTCAGGCAGAAAGTCAG
MluI rpsL F	AATAACGCGTCCGCTCTTGCCGACATGGTG
MluI rpsL R	AATACGCGTTAGGCGGCCGACGTGCCTAATTG
SacI MC amiC F	TAATGAGCTCCCGAACGAGGACGCGAAAGCC
SpeI MC amiC R	GCCGACTAGTACCGCCTTTTCAATCAACCC
Kan F BamHI	CAGGATCCAAAGCCAGTCCGCAGAAACG
Kan R BamHI	CTGGATCCTGGGCGAAGAACTCCAGCAT
NlpD DUS F	ATGCCGTCTGAACTTTGCGCTTGAGAAGAACG
NlpD DUS R	TCTGTACTGTCTGCGGCTTC
SacI MC amiC -sigseq F	GATTAGAGCTCAAAACGGTACGCGCACCAC
EcoRI MC amiC -stop codon R	GTGCAGAATTCACCCCGCTTCAATACGGATG
HindIII amiC down F	GCACGAAGCTTTAGTTGTCGGATGAAGGCAG
XhoI amiC down R	GACGACTCGAGCAACCATTTCAATTCCGTATCC
SacI MC nlpD -sigseq F	GATTAGAGCTCGCTACCCAGCAGCCTGCC
EcoRI MC nlpD -stop codon R	GCGCAGAATTCGAACGCGATATAGCTGTTC
HindIII nlpD down F	GCAGCAAGCTTCTGCCTGAAATCAAGTTGG
XhoI nlpD down R	GATTACTCGAGATCGGCATCCGTGTCGAAGC

REFERENCES

1. **Cohn, AC, MacNeil, JR, Harrison, LH, Hatcher, C, Theodore, J, Schmidt, M, Pondo, T, Arnold, KE, Baumbach, J, Bennett, N, Craig, AS, Farley, M, Gershman, K, Petit, S, Lynfield, R, Reingold, A, Schaffner, W, Shutt, KA, Zell, ER, Mayer, LW, Clark, T, Stephens, D, and Messonnier, NE.** 2010. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. **50**: 184-91.

2. **Kirsch, EA, Barton, RP, Kitchen, L, and Giroir, BP.** 1996. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. **15**: 967-78; quiz 979.

3. **Stephens, DS, Greenwood, B, and Brandtzaeg, P.** 2007. Epidemic meningitis, meningococcaemia, and *Neisseria meningitidis*. Lancet. **369**: 2196-2210.

4. **Yezli, S, Wilder-Smith, A, and Bin Saeed, AA.** 2016. Carriage of *Neisseria meningitidis* in the Hajj and Umrah mass gatherings. Int J Infect Dis. **47**: 65-70.

5. **Pizza, M and Rappuoli, R.** 2015. *Neisseria meningitidis*: pathogenesis and immunity. Curr Opin Microbiol. **23**: 68-72.

6. **Johswich, K.** 2017. Innate immune recognition and inflammation in *Neisseria meningitidis* infection. Pathog Dis. **75**: doi: 10.1093/femspd/ftx022.

7. **Doran, KS, Fulde, M, Gratz, N, Kim, BJ, Nau, R, Prasadarao, N, Schubert-Unkmeir, A, Tuomanen, EI, and Valentin-Weigand, P.** 2016. Host-pathogen interactions in bacterial meningitis. Acta Neuropathol. **131**: 185-209.

8. **Woodhams, KL, Chan, JM, Lenz, JD, Hackett, KT, and Dillard, JP.** 2013. Peptidoglycan fragment release from *Neisseria meningitidis*. Infect Immun. **81**: 3490-8.

9. **Vollmer, W, Blanot, D, and de Pedro, MA.** 2008. Peptidoglycan structure and architecture. FEMS Microbiol Rev. **32**: 149-67.

10. **Schleifer, KH and Kandler, O.** 1972. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev. **36**: 407-77.

11. **Höltje, JV.** 1995. From growth to autolysis: the murein hydrolases in *Escherichia coli*. Arch Microbiol. **164**: 243-54.

12. **Rosenthal, RS.** 1979. Release of soluble peptidoglycan from growing gonococci: hexaminidase and amidase activities. Infect Immun. **24**: 869-78.

13. **Park, JT and Uehara, T.** 2008. How bacteria consume their own exoskeletons (turnover and recycling of cell wall peptidoglycan). Microbiol Mol Biol Rev. **72**: 211-27.

14. **Johnson, JW, Fisher, JF, and Mobashery, S.** 2013. Bacterial cell-wall recycling. Ann N Y Acad Sci. **1277**: 54-75.

15. **Chan, JM and Dillard, JP.** 2017. Attention seeker: Production, modification, and release of inflammatory peptidoglycan fragments in *Neisseria* species. J Bacteriol. **199**: e00354-17.

16. **Heiss, LN, Moser, SA, Unanue, ER, and Goldman, WE.** 1993. Interleukin-1 is linked to the respiratory epithelial cytopathology of pertussis. Infect Immun. **61**: 3123-3128.

17. **Melly, MA, McGee, ZA, and Rosenthal, RS.** 1984. Ability of monomeric peptidoglycan fragments from *Neisseria gonorrhoeae* to damage human fallopian-tube mucosa. J Infect Dis. **149**: 378-386.

18. **Chamaillard, M, Hashimoto, M, Horie, Y, Masumoto, J, Qiu, S, Saab, L, Ogura, Y, Kawasaki, A, Fukase, K, Kusumoto, S, Valvano, MA, Foster, SJ, Mak, TW, Nunez, G, and Inohara, N.** 2003. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. **4**: 702-7.

19. **Girardin, SE, Boneca, IG, Carneiro, LA, Antignac, A, Jehanno, M, Viala, J, Tedin, K, Taha, MK, Labigne, A, Zahringer, U, Coyle, AJ, DiStefano, PS, Bertin, J, Sansonetti, PJ, and Philpott, DJ.** 2003. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. **300**: 1584-7.

20. **Girardin, SE, Travassos, LH, Herve, M, Blanot, D, Boneca, IG, Philpott, DJ, Sansonetti, PJ, and Mengin-Lecreulx, D.** 2003. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J Biol Chem. **278**: 41702-8.

21. **Ghosh, M, Shen, Z, Fahey, JV, Crist, SG, Patel, M, Smith, JM, and Wira, CR.** 2013. Pathogen recognition in the human female reproductive tract: expression of intracellular cytosolic sensors NOD1, NOD2, RIG-1, and MDA5 and response to HIV-1 and *Neisseria gonorrhea*. Am J Reprod Immunol. **69**: 41-51.

22. **Vijayrajratnam, S, Pushkaran, AC, Balakrishnan, A, Vasudevan, AK, Biswas, R, and Mohan, CG.** 2016. Bacterial peptidoglycan with amidated meso-diaminopimelic acid evades NOD1 recognition: an insight into NOD1 structure-recognition. Biochem J. **473**: 4573-4592.

23. **Schaub, RE, Chan, YA, Lee, M, Hesek, D, Mobashery, S, and Dillard, JP.** 2016. Lytic transglycosylases LtgA and LtgD perform distinct roles in remodeling, recycling and releasing peptidoglycan in *Neisseria gonorrhoeae*. Mol Microbiol. **102**: 865-881.

24. **Chan, YA, Hackett, KT, and Dillard, JP.** 2012. The lytic transglycosylases of *Neisseria gonorrhoeae*. Microb Drug Resist. **18**: 271-9.

25. **Schaub, RE, Perez-Medina, KM, Hackett, KT, Garcia, DL, and Dillard, JP.** 2019. *Neisseria gonorrhoeae* PBP3 and PBP4 facilitate NOD1 agonist peptidoglycan fragment release and survival in stationary phase. Infect Immun. **87**: e00833-18w.

26. **Woodhams, KL.** 2013. Characterization of the gonococcal genetic island and peptidoglycan fragment release in *Neisseria meningitidis*. University of Wisconsin-Madison.

27. **Lenz, JD, Hackett, KT, and Dillard, JP.** 2017. A single dual-function enzyme controls the production of inflammatory NOD agonist peptidoglycan fragments by *Neisseria gonorrhoeae*. MBio. **8**: e01464-17.

28. **Lenz, JD, Stohl, EA, Robertson, RM, Hackett, KT, Fisher, K, Xiong, K, Lee, M, Hesek, D, Mobashery, S, Seifert, HS, Davies, C, and Dillard, JP.** 2016. Amidase activity of AmiC controls cell separation and stem peptide release and is enhanced by NlpD in *Neisseria gonorrhoeae*. J Biol Chem. **291**: 10916-33.

29. **Stohl, EA, Lenz, JD, Dillard, JP, and Seifert, HS.** 2016. The gonococcal NlpD protein facilitates cell separation by activating peptidoglycan cleavage by AmiC. J Bacteriol. **198**: 615-22.

30. **Garcia, DL and Dillard, JP.** 2006. AmiC functions as an *N*-acetylmuramyl-L-alanine amidase necessary for cell separation and can promote autolysis in *Neisseria gonorrhoeae*. J Bacteriol. **188**: 7211-21.

31. **Cloud, KA and Dillard, JP.** 2004. Mutation of a single lytic transglycosylase causes aberrant septation and inhibits cell separation of *Neisseria gonorrhoeae*. J Bacteriol. **186**: 7811-4.

32. **Adu-Bobie, J, Lupetti, P, Brunelli, B, Granoff, D, Norais, N, Ferrari, G, Grandi, G, Rappuoli, R, and Pizza, M.** 2004. GNA33 of *Neisseria meningitidis* is a lipoprotein required for cell separation, membrane architecture and virulence. Infect Immun. **72**: 1914-9.

33. **Bhoopalan, SV, Piekarowicz, A, Lenz, JD, Dillard, JP, and Stein, DC.** 2016. *nagZ* triggers gonococcal biofilm disassembly. Sci Rep. **6**: 22372.

34. **Xu, Q, Mengin-Lecreulx, D, Liu, XW, Patin, D, Farr, CL, Grant, JC, Chiu, HJ, Jaroszewski, L, Knuth, MW, Godzik, A, Lesley, SA, Elsliger, MA, Deacon, AM, and Wilson, IA.** 2015. Insights into substrate specificity of NlpC/P60 cell wall hydrolases containing bacterial SH3 domains. mBio. **6**: e02327-14.

35. **Sinha, RK and Rosenthal, RS.** 1980. Release of soluble peptidoglycan from growing gonococci: demonstration of anhydro-muramyl-containing fragments. Infect. Immun. **29**: 914-925.

36. **Chan, JM and Dillard, JP.** 2016. *Neisseria gonorrhoeae* crippled its peptidoglycan fragment permease to facilitate toxic peptidoglycan monomer release. J Bacteriol. **198**: 3029-3040.

37. **Goodell, EW and Schwarz, U.** 1985. Release of cell wall peptides into culture medium by exponentially growing *Escherichia coli*. J Bacteriol. **162**: 391-7.

38. **Dillard, JP.** Peptidoglycan metabolism and fragment production, in *Pathogenic Neisseria*, J.K. Davies and C.M. Kahler, Editors. 2014, Caister Academic Press: Norfolk, UK.

39. **Berhardt, TG and de Boer, PAJ.** 2003. The *Escherichia coli* amidase AmiC is a periplasmic septal ring component exported via the twin-arginine transport pathway. Mol. Microbiol. **48**: 1171-1182.

40. **Uehara, T, Parzych, KR, Dinh, T, and Bernhardt, TG.** 2010. Daughter cell separation is controlled by cytokinetic ring-activated cell wall hydrolysis. EMBO J. **29**: 1412-22.

41. **Girardin, SE, Boneca, IG, Viala, J, Chamaillard, M, Labigne, A, Thomas, G, Philpott, DJ, and Sansonetti, PJ.** 2003. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. **278**: 8869-72.

42. **Inohara, N, Ogura, Y, Fontalba, A, Gutierrez, O, Pons, F, Crespo, J, Fukase, K, Inamura, S, Kusumoto, S, Hashimoto, M, Foster, SJ, Moran, AP, Fernandez-Luna, JL, and Nunez, G.** 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. **278**: 5509-12.

43. **Knilans, KJ, Hackett, KT, Anderson, JE, Weng, C, Dillard, JP, and Duncan, JA.** 2017. *Neisseria gonorrhoeae* lytic transglycosylases LtgA and LtgD reduce host innate immune signaling through TLR2 and NOD2. ACS Infect Dis. **3**: 624-633.

44. **Heidrich, C, Templin, MF, Ursinus, A, Merdanovic, M, Berger, J, Schwarz, H, de Pedro, MA, and Höltje, JV.** 2001. Involvement of *N*-acetylmuramyl-L-alanine amidases in cell separation and antibiotic-induced autolysis of *Escherichia coli*. Mol Microbiol. **41**: 167-178.

45.   **Tsang, MJ, Yakhnina, AA, and Bernhardt, TG.** 2017. NlpD links cell wall remodeling and outer membrane invagination during cytokinesis in *Escherichia coli*. PLoS Genet. **13**: e1006888.

46.   **Anantharaman, V and Aravind, L.** 2003. Evolutionary history, structural features and biochemical diversity of the NlpC/P60 superfamily of enzymes. Genome Biol. **4**: R11.

47.   **Uehara, A, Sugawara, Y, Kurata, S, Fujimoto, Y, Fukase, K, Kusumoto, S, Satta, Y, Sasano, T, Sugawara, S, and Takada, H.** 2005. Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells. Cell Microbiol. **7**: 675-86.

48.   **Möll, A, Dörr, T, Alvarez, L, Chao, MC, Davis, BM, Cava, F, and Waldor, MK.** 2014. Cell separation in *Vibrio cholerae* is mediated by a single amidase whose action is modulated by two nonredundant activators. J Bacteriol. **196**: 3937-48.

49.   **Horvath, DJ, Jr., Li, B, Casper, T, Partida-Sanchez, S, Hunstad, DA, Hultgren, SJ, and Justice, SS.** 2011. Morphological plasticity promotes resistance to phagocyte killing of uropathogenic *Escherichia coli*. Microbes Infect. **13**: 426-37.

50.   **Morse, SA and Bartenstein, L.** 1974. Factors affecting autolysis of *Neisseria gonorrhoeae*. Proc Soc Exp Biol Med. **145**: 1418-1421.

51.   **Kellogg, DS, Jr., Peacock, WL, Jr., Deacon, WE, Brown, L, and Pirkle, CL.** 1963. *Neisseria gonorrhoeae*. I. Virulence genetically linked to clonal variation. J. Bacteriol. **85**: 1274-1279.

52.   **Dillard, JP.** 2011. Genetic manipulation of *Neisseria gonorrhoeae*. Current Protocols in Microbiology. **23**: 4A.1.1-4A.1.24. doi: 10.1002/9780471729259.mc04a02s23.

53.   **Goodman, SD and Scocca, JJ.** 1988. Identification and arrangement of the DNA sequence recognized in specific transformation of *Neisseria gonorrhoeae*. Proc. Natl. Acad. Sci. USA. **85**: 6982-6986.

54.   **Garcia, DL and Dillard, JP.** 2008. Mutations in *ampG* or *ampD* affect peptidoglycan fragment release from *Neisseria gonorrhoeae*. J. Bacteriol. **190**: 3799-3807.

55.   **Sprong, T, Brandtzaeg, P, Fung, M, Pharo, AM, Hoiby, EA, Michaelsen, TE, Aase, A, van der Meer, JW, van Deuren, M, and Mollnes, TE.** 2003. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood. **102**: 3702-10.

56.   **Woodhams, KL, Benet, ZL, Blonsky, SE, Hackett, KT, and Dillard, JP.** 2012. Prevalence and detailed mapping of the gonococcal genetic island in *Neisseria meningitidis*. J Bacteriol. **194**: 2275-85.

57.   **Ram, S, Cox, AD, Wright, JC, Vogel, U, Getzlaff, S, Boden, R, Li, J, Plested, JS, Meri, S, Gulati, S, Stein, DC, Richards, JC, Moxon, ER, and Rice, PA.** 2003. Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem. **278**: 50853-62.

58.   **Seifert, HS, Chen, EY, So, M, and Heffron, F.** 1986. Shuttle mutagenesis: a method of transposon mutagenesis for *Saccharomyces cervisiae*. Proc. Natl. Acad. Sci. USA. **83**: 735-739.

59. **Cloud, KA and Dillard, JP.** 2002. A lytic transglycosylase of *Neisseria gonorrhoeae* is involved in peptidoglycan-derived cytotoxin production. Infect. Immun. **70**: 2752-2757.

60. **Ramsey, ME, Hackett, KT, Kotha, C, and Dillard, JP.** 2012. New complementation constructs for inducible and constitutive gene expression in *Neisseria gonorrhoeae* and *Neisseria meningitidis*. Appl Environ Microbiol. **78**: 3068-78.

61. **Ramsey, ME, Hackett, KT, Bender, T, Kotha, C, van der Does, C, and Dillard, JP.** 2014. TraK and TraB are conserved outer membrane proteins of the *Neisseria gonorrhoeae* Type IV secretion system and are expressed at low levels in wild-type cells. J Bacteriol. **196**: 2954-68.